AbbVie blocks Humira antitrust suit

Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ‘legal standing’.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Europe

UPC upholds injunction in Invisalign maker’s software dispute with rival

9 July 2026 China-headquartered Angelalign failed to convince UPC appellate judges to overturn a ban that affects its ability to offer orthodontic planning software in Europe with certain functionality.

Europe

BioNTech and Pfizer secure big European win over mRNA patent

8 July 2026 UPC judges revoke a patent asserted against the companies over their Comirnaty COVID-19 vaccine, in a ruling that clarified the court’s key principles on exclusive licences, novelty and inventive step.

Europe

UPC revives patent, but timing sinks Guardant’s appeal

6 July 2026 The Unified Patent Court delivers a mixed ruling in a dispute over liquid biopsy technology, overturning a finding that a patent was likely invalid while refusing to grant interim relief because of the patent owner’s delay.

More features

Sanofi launches mRNA lawsuits on Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

AbbVie blocks Humira antitrust suit

More on this story

Editor's picks

Editor's picks

More features